Thalys(603716)2024-10-28 09:53Financial Performance - The company's operating revenue for Q3 2024 was ¥444,423,888.93, representing a decrease of 14.31% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was -¥51,252,564.76, with a year-to-date net profit of -¥56,025,062.27[2]. - The net profit for Q3 2024 was -33,512,646.83 RMB, compared to a net profit of 17,789,385.69 RMB in Q3 2023, indicating a significant decline[20]. - The total operating revenue for the first three quarters of 2024 was approximately ¥293.29 million, a decrease of 12.06% compared to ¥333.59 million in the same period of 2023[29]. - The net profit for the first three quarters of 2024 was approximately ¥1.23 million, a significant improvement from a net loss of ¥41.08 million in the same period of 2023[29]. - The company reported a comprehensive income total of -44,182,467.30 RMB for Q3 2024, compared to 8,900,663.11 RMB in Q3 2023[21]. - The total comprehensive income for the first three quarters of 2024 was approximately -¥8.85 million, an improvement from -¥54.02 million in the same period of 2023[30]. Cash Flow - The cash flow from operating activities for Q3 2024 was ¥49,374,084.98, a significant decrease of 99.50% year-to-date[2]. - The cash flow from operating activities for the first three quarters of 2024 was 496,140.58 RMB, a significant drop from 99,367,160.38 RMB in the same period of 2023[22]. - The cash flow from investment activities decreased by 53.82% mainly due to a reduction in the recovery of investment-related receivables[11]. - The net cash flow from investment activities was 7,540,032.26 RMB, a decrease of 53.8% compared to 16,328,334.46 RMB in the previous year[23]. - The company's cash and cash equivalents at the end of the period were 252,506,148.12 RMB, down from 337,098,538.85 RMB, indicating a decrease of about 25.1%[23]. Assets and Liabilities - The total assets at the end of Q3 2024 were ¥3,134,268,796.81, down 6.21% from the end of the previous year[4]. - Current assets decreased to CNY 2,257,448,892.53 from CNY 2,394,715,901.95 as of December 31, 2023, reflecting a decline of approximately 5.73%[16]. - Total liabilities decreased to CNY 1,989,415,054.52 from CNY 2,027,091,715.60, a reduction of about 1.86%[17]. - The total equity decreased to 1,174,736,117.95 RMB from 1,207,345,858.09 RMB, reflecting a decrease of approximately 2.7%[27]. Shareholder Information - The company had a total of 27,636 common shareholders at the end of the reporting period[12]. - The top shareholder, Shanghai Saihai Health Technology Co., Ltd., holds 10.75% of the shares[12]. - The company repurchased 14,348,740 shares, accounting for 7.13% of the total share capital[14]. Research and Development - The company increased its R&D investment in smart hospitals and medical big data analysis, leading to higher R&D expenses[5]. - Research and development expenses increased to 31,457,970.43 RMB in Q3 2024 from 27,362,017.64 RMB in Q3 2023, reflecting a focus on innovation[20]. - Research and development expenses increased to approximately ¥17.77 million, up 318.36% from ¥4.24 million in the first three quarters of 2023[29]. Other Financial Metrics - The company reported a basic and diluted earnings per share of -¥0.26 for Q3 2024[4]. - Basic earnings per share for Q3 2024 were -0.28 RMB, compared to -0.02 RMB in Q3 2023[21]. - The company experienced a net loss of -56,025,062.27 RMB attributable to shareholders in Q3 2024, compared to a loss of -3,814,605.05 RMB in Q3 2023[21]. - The total operating expenses for Q3 2024 were 1,137,695,865.90 RMB, down from 1,214,470,004.09 RMB in Q3 2023[20]. - The company reported a decrease in sales expenses to 100,018,355.49 RMB in Q3 2024 from 93,480,054.04 RMB in Q3 2023, indicating a shift in cost management strategy[20].